about
T Regulatory and T Helper 17 Cells in Primary Sjögren's Syndrome: Facts and PerspectivesNerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma)IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?Myositis in primary Sjögren's syndrome: data from a multicentre cohort.Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications.Cellular players in angiogenesis during the course of systemic sclerosis.Angiogenic cytokines and growth factors in systemic sclerosis.Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosisImpaired endothelium-mesenchymal stem cells cross-talk in systemic sclerosis: a link between vascular and fibrotic features.Rituximab in primary Sjögren's syndrome: a ten-year journey.CD4(-)CD8(-) T-cells in primary Sjögren's syndrome: association with the extent of glandular involvement.Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.The role of IL-1β in the bone loss during rheumatic diseases.Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literatureMacitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts.Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation?Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways.Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy.Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS.Unmasking the pathogenic role of IL-17 axis in primary Sjögren's syndrome: a new era for therapeutic targeting?Methotrexate: an old new drug in autoimmune disease.Stem cell therapies for systemic sclerosis.Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease.Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies.Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?Endothelial progenitor cells: Are they displaying a function in autoimmune disorders?Interleukin-9 and T helper type 9 cells in rheumatic diseases.H-ferritin and CD68(+) /H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease.A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis.Tocilizumab for the treatment of adult-onset Still's disease: results from a case series.The CD68(+)/H-ferritin(+) cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue: correlation with disease severity and implication for pBiologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study.Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation:Association of psoriasis and/or psoriatic arthritis with autoimmune diseases: the experience of two Italian integrated Dermatology/Rheumatology outpatient clinics.Searching for a good model for systemic sclerosis: the molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis.Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis.Early assessment of sub-clinical cardiac involvement in systemic sclerosis (SSc) using delayed enhancement cardiac magnetic resonance (CE-MRI).Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy.Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis.Combination therapy with cyclosporine and methotrexate in patients with early rheumatoid arthritis soon inhibits TNFalpha production without decreasing TNFalpha mRNA levels. An in vivo and in vitro study.
P50
Q26859226-F307836D-50D1-4639-85CA-D2EA3ECBA54AQ28362581-407BE9F0-170D-4269-9536-CCC8C7466064Q30251741-68627E51-6655-4542-A54E-4B5AA3A07050Q30974806-14DAE048-7A6B-493C-935E-BE9C53692170Q33256082-5E7BD2D8-1132-439A-A176-508DC77BB544Q34183211-8273EB6F-9E9C-41D8-AE1B-453D046031DEQ34183304-E998D53D-3CF5-4780-BDB6-2A3BFE612683Q34199111-6DC8C0A3-20AD-4215-BAD4-F1CA52D78CABQ34389943-FFE395AF-EB45-48BD-989A-27B65CE1D289Q34432465-D6B5D440-CD3C-44B0-ACCD-62206B8E30BEQ35086094-8D2393E1-B658-4635-ACED-846C7DE17FC8Q35115790-38CD64D4-1D52-4905-BC5B-3569B0175A85Q35540844-6A44A67B-3C25-495D-845E-4214695C75DCQ35687532-563E4CF2-926D-4CD1-AD3D-9655E30E15FDQ36051223-575BBD8A-0C05-427A-869A-92D4274DDAF3Q37872399-0FB7D5DC-E261-4421-993D-5D132EF59AA5Q38062771-5DA1BFB3-0FDB-4A49-955A-0B484D8E3845Q38062772-C4201809-BFA3-4072-AC3D-F0F5B0F5B983Q38103284-271CDBFC-D370-4D42-9559-245463B24EB4Q38245657-05992F67-7CAB-400C-81F1-808032B70FC0Q38253237-47DE9402-76EC-47DC-BF1C-2E958571CF93Q38265814-2D20E4E6-E0C7-4B64-B561-187FD5D85AFCQ38323485-2E1B2B1E-F1A2-468C-9992-A6558AC840ACQ38354793-06F9DF13-230E-4144-A74D-F771D3449072Q38364657-57D707AD-AB53-4201-A50A-9AAF844BD316Q38827773-301B38DB-00DA-45DB-BFFC-E47B6BD58461Q38829766-74AC6C92-FFE0-4B15-B2CE-69F56B4906D6Q39673488-E6415819-5452-4062-9645-32D03FD9748DQ39955870-FF3A6ED0-0B6D-43C6-94D4-7DA3943EDF7BQ40235629-4AD38A35-F6D6-4FCF-BA24-67BF5624A786Q40352271-305DF4D4-1197-4A17-B26D-73E37D838086Q40484547-FA0B1530-C6F2-4A64-B130-4D4AE8B43E2FQ40815110-F33EAF86-9056-4271-B15A-ABD8C77A9FFDQ41060904-CA977265-3C90-4A97-9D92-A984F7B8F420Q42416370-6182DE49-47F7-4BCF-A81B-3766C317DA71Q42621913-2FB22E23-C6BD-4C15-9CF8-8748C1FCBB40Q43438571-B3F23B59-B12D-46EB-B57F-A8723E7F00EBQ43871288-645296AE-298B-47A8-8EE0-625F37855D48Q43956898-0D44FDA6-EE9E-4BFF-A430-081E10D64E4EQ44053149-5BFAAF2A-35ED-4961-8208-228462E220CC
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Paola Cipriani
@ast
Paola Cipriani
@en
Paola Cipriani
@es
Paola Cipriani
@nl
Paola Cipriani
@sl
type
label
Paola Cipriani
@ast
Paola Cipriani
@en
Paola Cipriani
@es
Paola Cipriani
@nl
Paola Cipriani
@sl
prefLabel
Paola Cipriani
@ast
Paola Cipriani
@en
Paola Cipriani
@es
Paola Cipriani
@nl
Paola Cipriani
@sl
P106
P1153
7005841263
P21
P214
5031149235101376690000
P31
P496
0000-0002-2000-4661
P734
P735
P7859
lccn-n94117513